Advagene Biopharma Co., Ltd.
Taipei Exchange 6709.TWO
Advagene Biopharma Co., Ltd. EBITDA for the year ending December 31, 2023: USD -2.61 M
Advagene Biopharma Co., Ltd. EBITDA is USD -2.61 M for the year ending December 31, 2023, a 25.06% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
-
Advagene Biopharma Co., Ltd. EBITDA for the year ending December 31, 2022 was USD -3.48 M, a -13.73% change year over year.
-
Advagene Biopharma Co., Ltd. EBITDA for the year ending December 31, 2021 was USD -3.06 M, a -38.46% change year over year.
-
Advagene Biopharma Co., Ltd. EBITDA for the year ending December 31, 2020 was USD -2.21 M, a 29.88% change year over year.
-
Advagene Biopharma Co., Ltd. EBITDA for the year ending December 31, 2019 was USD -3.15 M.
Key data
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
Market news
Loading...
Taipei Exchange: 6709.TWO
| CEO | Mr. Yu-Shen Hsu |
| IPO Date | Nov. 29, 2018 |
| Location | |
| Headquarters | No. 308, Neihu Road |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
Description
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, and COVID-19 immunotherapy. The company is based in Taipei, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email